Individualizing Therapy for Hemophilia A: Evaluating The Clinical Implications of Scientific Advances In Treatment and Dosing

Released On
November 21, 2019

Expires On
November 21, 2020

Media Type
Internet

Completion Time
120 minutes

Specialty
Hematology, Oncology

Topic(s)
Hemophilia

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Rush University Medical Center, in collaboration with ASiM CE LLC.

 

Supported by independent medical educational grants from Sanofi Genzyme and Shire.

Credit Available

  • Physicians — maximum of 2.0 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational initiative is intended to meet the needs of hematologists, other physicians, as well as allied healthcare practitioners (nurse practitioners and physician assistants) who care for patients with hemophilia A. There are no prerequisites.

Program Overview

This interactive Continuing Education (CE) monograph will provide hematologists, other physicians, and allied healthcare providers (including nurse practitioners and physician assistants), who care for patients with hemophilia A, with the knowledge and skills necessary to make the most appropriate treatment choices for their patients, based on patient preferences and lifestyle and interpatient variability in pharmacokinetics, and to predict, prevent, and manage inhibitor formation.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • REVIEW advances in factor-based prophylaxis, including extended half-life factors, for managing hemophilia.
  • DESCRIBE the impact of interpatient variability in clotting factor PK profiles on subsequent bleeding risk and related limitations of weight-based dosing.
  • EVALUATE recent clinical and technological advances to optimize clotting factor dosing on an individual patient basis.
  • ASSESS current and emerging strategies to predict and manage inhibitor development.
  • PROPOSE patient-specific prophylactic treatment paradigms for hemophilia A considering the latest evidence-based knowledge.

Faculty

FACULTY NAME and TITLE

Mindy L. Simpson, MD (Chair)

Assistant Professor of Pediatrics
Pediatric Hematology/Oncology
Director, Rush Hemophilia and Thrombophilia Center
Rush University Medical Center
Chicago, Illinois

FACULTY NAME and TITLE

Lisa N. Boggio, MD

Assistant Professor of Pediatrics
Rush University Medical Center
Rush Hemophilia and Thrombophilia Center
Chicago, Illinois

Physician Accreditation Statement

In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Credit Designation

Rush University Medical Center designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

After reviewing this activity, participants may receive a certificate by receiving a score of 80% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.

Disclosures of Conflicts of Interest

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias, and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

Unapproved Uses of Drugs/Devices: In accordance with requirements of the US Food and Drug Administration (FDA), the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information. The following relationships have been reported for this activity:

Dr Boggio

  • Consultant: Baxalta Inc, Bayer, Bioverativ Inc, CSL Behring, Novo Nordisk, Takeda Pharmaceutical Company Ltd, and Octapharma.

Dr Simpson

  • Speakers' Bureaus: Bayer and Novo Nordisk
  • Consultant: Bayer, CSL Behring, Genentech Inc, HEMA Biologics, Novo Nordisk, Octapharma, and Takeda Pharmaceutical Company Ltd.

Instructions for Participation and Credit

The following is an interactive CE monograph designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, an interactive monograph, and a CME postassessment and evaluation. You will have 3 chances to pass the postassessment; the passing grade is 80%. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the activity.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.